VERV - Crispr Intellia and Recursion gain as Ark ETFs boost stakes
2024-02-14 15:41:42 ET
More on CRISPR, Intellia Therapeutics, etc.
- Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
- Crispr Therapeutics: Investors Bet Against Casgevy Uptake
- Biotech And Pharma Diversification Pays Off
- Vertex, CRISPR gene therapy approved in EU for sickle cell disease, beta-thalassemia
- CRISPR CMO who resigned after Casgevy approval lands at Takeda